Clinical trial improves neurocognitive outcomes for childhood craniopharyngioma

St. Jude Children’s Research Hospital is reporting phase 2 clinical trial results treating the brain tumor craniopharyngioma with proton therapy. The researchers found a similar survival rate between more targeted proton therapy and photon therapy but improved neurocognitive outcomes with the proton therapy. The clinical trial may set the new “gold standard” for pediatric craniopharyngioma treatment. The study was published today in Lancet Oncology.

COVID vaccination found to have lower risk of autoantibodies than natural immunity

Since the introduction of SARS-CoV-2 mRNA vaccines, there has been an ongoing debate about whether vaccinations or natural immunity provide superior protection. New research shows that while both build immunity to the virus, mRNA vaccines side-step the development of self-attacking antibodies—known as autoantibodies—that frequently occur in COVID-19 patients.

Opioid exposure in the womb could raise the risk of heart disease later in life

A new study sheds light on an understudied aspect of today’s opioid crisis: What happens to the cardiovascular health of babies exposed to opioids in the womb. The outcomes of the study suggest that children born to mothers who use opioids during pregnancy may be more likely to develop chronic diseases as adults, including cardiovascular and metabolic diseases. Researchers will present their work this week at the American Physiology Summit, the flagship annual meeting of the American Physiological Society (APS), in Long Beach, California.